regulatory
confidence high
sentiment negative
materiality 0.75
Propanc Biopharma receives Nasdaq delisting notice; no 180-day cure period due to prior reverse split
Propanc Biopharma, Inc.
- Nasdaq notice dated Oct 23, 2026: PPCB closed below $1.00 minimum bid for the 30 consecutive business days before Oct 21, 2026.
- Company is ineligible for the standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) because it effected a reverse stock split in the prior year.
- Delisting set for Nov 2, 2026 unless Propanc appeals to a Nasdaq Hearings Panel by Oct 30, 2026; the company says it intends to appeal.
- Propanc claims it has cured the bid price deficiency since receiving the notice; appeal would stay delisting pending the Panel's decision.
- Company cites risks: reduced liquidity, fewer investors, loss of registration statement access, and impaired employee equity incentives.